iTeos Therapeutics (ITOS) Short Interest Ratio & Short Volume $8.32 +0.19 (+2.34%) (As of 11/22/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends iTeos Therapeutics Short Interest DataiTeos Therapeutics (ITOS) has a short interest of 3.12 million shares, representing 11.11% of the float (the number of shares available for trading by the public). This marks a -18.32% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.7, indicating that it would take 4.7 days of the average trading volume of 444,601 shares to cover all short positions.Current Short Interest3,120,000 sharesPrevious Short Interest3,820,000 sharesChange Vs. Previous Month-18.32%Dollar Volume Sold Short$26.36 millionShort Interest Ratio4.7 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares36,534,000 sharesFloat Size28,080,000 sharesShort Percent of Float11.11%Today's Trading Volume297,091 sharesAverage Trading Volume444,601 sharesToday's Volume Vs. Average67% Short Selling iTeos Therapeutics? Sign up to receive the latest short interest report for iTeos Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartITOS Short Interest Over TimeITOS Days to Cover Over TimeITOS Percentage of Float Shorted Over Time Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now iTeos Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20243,120,000 shares $26.36 million -18.3%11.1%4.7 $8.45 10/15/20243,820,000 shares $35.98 million -20.8%13.6%6.3 $9.42 9/30/20244,820,000 shares $49.21 million +92.0%17.2%9.3 $10.21 9/15/20242,510,000 shares $41.92 million -3.8%8.9%5 $16.70 8/31/20242,610,000 shares $43.98 million +4.4%9.3%7.3 $16.85 8/15/20242,500,000 shares $38.53 million -0.8%8.9%7.4 $15.41 Get the Latest News and Ratings for ITOS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20242,520,000 shares $44.33 million -4.2%9.1%5.6 $17.59 7/15/20242,630,000 shares $43.63 million +1.2%9.5%6 $16.59 6/30/20242,600,000 shares $38.58 million +16.1%9.4%6 $14.84 6/15/20242,240,000 shares $36.36 million +8.2%8.1%5.1 $16.23 5/31/20242,070,000 shares $34.65 million -4.2%7.5%5.2 $16.74 5/15/20242,160,000 shares $38.79 million +4.4%7.8%5.2 $17.96 4/30/20242,070,000 shares $22.23 million -2.4%7.2%7.2 $10.74 4/15/20242,120,000 shares $24.93 million +3.4%7.4%7.7 $11.76 3/31/20242,050,000 shares $27.96 million +2.0%7.2%7.2 $13.64 3/15/20242,010,000 shares $21.73 million +11.7%7.1%7.8 $10.81 2/29/20241,800,000 shares $19.28 million +5.9%6.3%6 $10.71 2/15/20241,700,000 shares $17.12 million -1.7%6.0%5.5 $10.07 1/31/20241,730,000 shares $17.21 million +16.1%6.1%5.7 $9.95 1/15/20241,490,000 shares $16.88 million -6.9%5.2%4.5 $11.33 12/31/20231,600,000 shares $17.52 million -21.2%5.6%3.4 $10.95 12/15/20232,030,000 shares $22.03 million +17.3%7.1%4.3 $10.85 11/30/20231,730,000 shares $16.19 million +8.8%6.1%4 $9.36 11/15/20231,590,000 shares $16.01 million -9.1%5.6%3.7 $10.07 10/31/20231,750,000 shares $17.61 million -24.6%6.0%3.1 $10.06 10/15/20232,320,000 shares $20.97 million +28.2%7.9%4.3 $9.04 9/30/20231,810,000 shares $19.82 million +7.7%6.2%4.7 $10.95 9/15/20231,680,000 shares $20.70 million +3.7%5.7%4.4 $12.32 8/31/20231,620,000 shares $19.55 million +5.9%5.5%3.8 $12.07 8/15/20231,530,000 shares $18.21 million +8.5%5.3%3.5 $11.90 7/31/20231,410,000 shares $19.82 million -0.7%4.9%5.1 $14.06 7/15/20231,420,000 shares $19.51 million -6.0%4.9%5 $13.74 6/30/20231,510,000 shares $19.99 million -14.2%5.2%5.1 $13.24 6/15/20231,760,000 shares $24.99 million -7.4%6.1%6.1 $14.20 5/31/20231,900,000 shares $30.93 million +6.7%6.6%7.1 $16.28 5/15/20231,780,000 shares $26.52 million +6.6%6.1%7.3 $14.90 4/30/20231,670,000 shares $22.95 million -2.9%5.8%6.9 $13.74 4/15/20231,720,000 shares $23.50 million +1.8%5.9%6.8 $13.66 3/31/20231,690,000 shares $23.00 million +11.2%5.8%6.1 $13.61 3/15/20231,520,000 shares $23.91 million +2.0%5.3%5.2 $15.73Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide 2/28/20231,490,000 shares $26.39 million +0.7%5.2%4.7 $17.71 2/15/20231,480,000 shares $27.44 million +0.7%5.1%4.6 $18.54 1/31/20231,470,000 shares $30.72 million +0.7%5.1%4.4 $20.90 1/15/20231,460,000 shares $27.84 million +5.0%5.1%4.4 $19.07 12/30/20221,390,000 shares $27.15 million -22.8%4.8%4.3 $19.53 12/15/20221,800,000 shares $38.65 million +9.8%6.2%5.9 $21.47 11/30/20221,640,000 shares $33.05 million -12.3%5.7%5.4 $20.15 11/15/20221,870,000 shares $38.67 million -7.4%6.5%6.1 $20.68 10/31/20222,020,000 shares $39.35 million +3.1%7.0%6.3 $19.48 10/15/20221,960,000 shares $35.32 million -27.4%6.8%5.9 $18.02 9/30/20222,700,000 shares $51.44 million +0.4%9.4%7.5 $19.05 9/15/20222,690,000 shares $54.61 million -0.4%9.3%7.1 $20.30 8/31/20222,700,000 shares $59.89 million -5.6%9.4%6.8 $22.18 8/15/20222,860,000 shares $72.64 million -1.7%9.9%6.8 $25.40 7/31/20222,910,000 shares $71.18 million +0.3%10.1%6.1 $24.46 7/15/20222,900,000 shares $71.05 million +4.3%10.1%5.8 $24.50 6/30/20222,780,000 shares $57.27 million +28.7%9.6%5.8 $20.60 6/15/20222,160,000 shares $39.68 million +9.6%7.5%4.4 $18.37 5/31/20221,970,000 shares $34.48 million +13.2%6.8%4.2 $17.50 5/15/20221,740,000 shares $32.33 million -17.9%6.0%4 $18.58 4/30/20222,120,000 shares $56.58 million +35.0%8.1%5.5 $26.69 4/15/20221,570,000 shares $51.28 million +9.8%6.0%4.1 $32.66 3/31/20221,430,000 shares $46.02 million +61.3%N/A0 $32.18 3/15/2022886,300 shares $31.84 million +0.0%3.5%1.7 $35.93 2/28/2022886,000 shares $32.01 million -4.0%3.5%1.8 $36.13 2/15/2022922,400 shares $33.27 million -30.1%3.9%1.8 $36.07 1/31/20221,320,000 shares $48.34 million -11.4%5.8%2.6 $36.62 1/15/20221,490,000 shares $59.09 million +108.5%N/A3.1 $39.66 12/31/2021714,800 shares $33.28 million +12.8%2.6%1.6 $46.56 12/15/2021633,700 shares $23.64 million +37.8%2.4%2.6 $37.31 11/30/2021460,000 shares $16.24 million -27.8%1.7%2.3 $35.30 11/15/2021636,900 shares $19.36 million -21.3%2.4%3.5 $30.40 10/29/2021809,500 shares $21.65 million +3.3%2.8%5.1 $26.75 10/15/2021784,000 shares $21.92 million -0.7%2.8%4.7 $27.96 9/30/2021789,300 shares $21.31 million +12.0%2.8%4.3 $27.00 9/15/2021704,600 shares $19.79 million -9.6%2.3%2.6 $28.09 8/31/2021779,500 shares $22.10 million -20.4%2.6%1.9 $28.35 8/13/2021979,000 shares $24.12 million -5.9%3.3%2 $24.64 7/30/20211,040,000 shares $24.99 million +11.2%3.5%2.2 $24.03 7/15/2021935,300 shares $22.58 million +11.1%3.2%2 $24.14 6/30/2021841,900 shares $21.59 million -49.9%2.9%1.8 $25.65 6/15/20211,680,000 shares $44.35 million -5.1%5.7%3.9 $26.40 5/28/20211,770,000 shares $36.36 million -8.3%6.0%5.9 $20.54 5/14/20211,930,000 shares $43.15 million +11.6%6.5%7.2 $22.36 4/30/20211,730,000 shares $41.36 million +11.6%5.9%7.1 $23.91 4/15/20211,550,000 shares $37.18 million +17.4%5.3%5.2 $23.99 3/31/20211,320,000 shares $42.73 million +128.4%4.5%4.7 $32.37 3/15/2021578,000 shares $22.62 million +24.4%2.0%2.1 $39.14 2/26/2021464,700 shares $19.42 million -5.9%1.6%2.1 $41.79 2/12/2021493,600 shares $17.92 million -13.8%1.7%2.4 $36.31Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide 1/29/2021572,300 shares $18.40 million +0.4%1.9%2.9 $32.15 1/15/2021569,800 shares $18.93 million No Change1.9%3.5 $33.22 ITOS Short Interest - Frequently Asked Questions What is iTeos Therapeutics' current short interest? Short interest is the volume of iTeos Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 3,120,000 shares of ITOS short. 11.11% of iTeos Therapeutics' shares are currently sold short. Learn More on iTeos Therapeutics' current short interest. What is a good short interest ratio for iTeos Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ITOS shares currently have a short interest ratio of 5.0. Learn More on iTeos Therapeutics's short interest ratio. Which institutional investors are shorting iTeos Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of iTeos Therapeutics: Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for iTeos Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.11% of iTeos Therapeutics' floating shares are currently sold short. Is iTeos Therapeutics' short interest increasing or decreasing? iTeos Therapeutics saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 3,120,000 shares, a decrease of 18.3% from the previous total of 3,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is iTeos Therapeutics' float size? iTeos Therapeutics currently has issued a total of 36,534,000 shares. Some of iTeos Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. iTeos Therapeutics currently has a public float of 28,080,000 shares. How does iTeos Therapeutics' short interest compare to its competitors? 11.11% of iTeos Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to iTeos Therapeutics: Taysha Gene Therapies, Inc. (8.61%), Vaxart, Inc. (4.95%), Calliditas Therapeutics AB (publ) (0.01%), Rocket Pharmaceuticals, Inc. (13.05%), ANI Pharmaceuticals, Inc. (10.27%), Mesoblast Limited (1.22%), Avadel Pharmaceuticals plc (9.82%), Gyre Therapeutics, Inc. (1.59%), Applied Therapeutics, Inc. (10.43%), Cogent Biosciences, Inc. (7.63%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short iTeos Therapeutics stock? Short selling ITOS is an investing strategy that aims to generate trading profit from iTeos Therapeutics as its price is falling. ITOS shares are trading up $0.19 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against iTeos Therapeutics? A short squeeze for iTeos Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ITOS, which in turn drives the price of the stock up even further. How often is iTeos Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ITOS, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Taysha Gene Therapies Short Interest Data Vaxart Short Interest Data Calliditas Therapeutics AB (publ) Short Interest Data Rocket Pharmaceuticals Short Interest Data ANI Pharmaceuticals Short Interest Data Mesoblast Short Interest Data Avadel Pharmaceuticals Short Interest Data Gyre Therapeutics Short Interest Data Applied Therapeutics Short Interest Data Cogent Biosciences Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ITOS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITOS Stock Alerts